CD45 Antibody (BL-178-12C7)

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-14668

Recombinant Monoclonal
Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP3-14668
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Human

Applications

Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, Immunoprecipitation, Multiplex Immunofluorescence, Western Blot

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Rabbit Clone # BL-178-12C7

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

View all CD45 Antibodies »

Product Specifications

Immunogen

between 1200 and 1250

Clonality

Monoclonal

Host

Rabbit

Scientific Data Images for CD45 Antibody (BL-178-12C7)

Western Blot: CD45 Antibody (BL-178-12C7) [NBP3-14668]

Western Blot: CD45 Antibody (BL-178-12C7) [NBP3-14668]

Western Blot: CD45 Antibody (BL-178-12C7) [NBP3-14668] - Whole cell lysate (50 ug) from Jurkat, HEK293T, MOLT-4, HeLa, and SR cells prepared using NETN lysis buffer.Antibody: Rabbit anti-CD45 recombinant monoclonal antibody [BL-178-12C7] used at 1:1000. Secondary: HRP-conjugated goat anti-rabbit IgG. Chemiluminescence with an exposure timeof 1 second. Lower Panel: Rabbit anti-COPB2 antibody.
Immunocytochemistry/ Immunofluorescence: CD45 Antibody (BL-178-12C7) [NBP3-14668]

Immunocytochemistry/ Immunofluorescence: CD45 Antibody (BL-178-12C7) [NBP3-14668]

Immunocytochemistry/Immunofluorescence: CD45 Antibody (BL-178-12C7) [NBP3-14668] - CD45 Antibody [NBP3-14668] - Antibody: Rabbit anti-CD45recombinant monoclonal antibody [BL-178-12C7](A700-012). Secondary: HRP-conjugated goat anti-rabbitIgG.Substrate: DAB.
Immunohistochemistry: CD45 Antibody (BL-178-12C7) [NBP3-14668]

Immunohistochemistry: CD45 Antibody (BL-178-12C7) [NBP3-14668]

Immunohistochemistry: CD45 Antibody [NBP3-14668] - Sample: FFPE section of human coloncarcinoma. Antibody: Rabbit anti-CD45 recombinant monoclonal antibody used at 1:250. Secondary: HRP-conjugated goat anti-rabbit IgG. Substrate: Opal™.Counterstain: DAPI (blue).
View 5 more images

Applications for CD45 Antibody (BL-178-12C7)

Application
Recommended Usage

Immunocytochemistry/ Immunofluorescence

1:100 - 1:500

Immunohistochemistry

1:100 - 1:500

Immunohistochemistry-Paraffin

1:100 - 1:500

Immunoprecipitation

20 ul/mg lysate

Western Blot

1:1000
Application Notes
Flow-1 ul per 1 X 10^6 cells. Epitope retrieval with citrate buffer pH 6.0 is recommended for FFPE tissue sections.

Formulation, Preparation, and Storage

Purification

>95%

Formulation

Borate Buffered Saline (BBS) pH 8.2 with 0.1% BSA and

Preservative

0.09% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 2 - 8 C / 1 year from date of receipt

Background: CD45

CD45, also known as leukocyte common antigen (LCA), T200, or Ly5, is a member C of the class 1 receptor-like protein tyrosine phosphatase (PTPRC) family (1, 2). It is a transmembrane glycoprotein which, due to alternative splicing, has a multiple isoforms with a theoretical molecular weight ranging from 180 - 220 kDa (1, 3-5). Human CD45 is synthesized as a 1281 amino acid sequence consisting of an alternatively spliced extracellular receptor-like region, a cysteine-rich domain, fibronectin-like III repeats, a transmembrane segment, and a cytoplasmic region with tandem protein tyrosine phosphatase (PTP) domains: the membrane proximal domain (D1) and the membrane distal domain (D2) (3, 5). CD45 is expressed on all nucleated hematopoietic cells and their precursors, except mature red blood cells, and is one of the most abundantly-expressed cell-surface glycoproteins, comprising approximately 10% of surface proteins in lymphocytes (3). Functionally, CD45 is essential for development and activation of T-cells and B-cells (1-5). More specifically, CD45 positively regulates antigen receptor signaling and Src-family member kinase activity (1, 3). There are many ways to regulate CD45 phosphatase activity including ligand binding, dimerization, protein interactions, cellular localization, and covalent modifications (3, 6). Ligands for CD45 include pUL11, a transmembrane protein of the cytomegalovirus RL11 (CMV RL11) family, and placental protein 14 (PP14), both of which exclusively bind CD45, and various lectins including CD22, galectin-1, galectin-3, macrophage mannose receptor (MR), and macrophage galactose-type lectin (MGL) (6).

Given its role in immune cell development and activation, CD45 has also been linked to a variety of diseases. The importance of CD45 in immunity has been revealed in human and mouse studies where CD45-deficiency leads to a severe-combined immunodeficiency (SCID) phenotype (2, 3, 6). A CD45-knockout mice study revealed inhibited thymocyte production and poor B-cell response, whereas CD45 activation in mice causes lymphoproliferation and autoantibody production (3). CD45 variants have been associated with altered immune function and autoimmune disorders including multiple sclerosis, systemic lupus erythematosus (SLE), and rheumatoid arthritis (6). Furthermore, altered CD45 expression has been implicated in oncological conditions including chronic lymphatic leukemia, acute lymphatic leukemia, Hodgkin lymphoma, multiple myeloma, and diffuse large B-cell lymphoma (6). Considering its role in autoimmune disorders, immunodeficiency and cancer, CD45 is an ideal therapeutic target (3, 6). The main approaches to control CD45 function is through either selective inhibitors or anti-CD45 antibodies (3).

Alternative names for CD45 includes B220, CD antigen: CD45, CD45 antigen, CD45R, EC 3.1.3.48, GP180, LCA, Leukocyte common antigen, LY5, protein tyrosine phosphatase receptor type c polypeptide, PTPRC, receptor-type tyrosine-protein phosphatase C, T200 Glycoprotein, and T200.

References

1. Trowbridge, I. S., & Thomas, M. L. (1994). CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annual review of immunology. https://doi.org/10.1146/annurev.iy.12.040194.000505

2. Andersen, J. N., Jansen, P. G., Echwald, S. M., Mortensen, O. H., Fukada, T., Del Vecchio, R., Tonks, N. K., & Moller, N. P. (2004). A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

3. Hermiston, M. L., Xu, Z., & Weiss, A. (2003). CD45: a critical regulator of signaling thresholds in immune cells. Annual review of immunology. https://doi.org/10.1146/annurev.immunol.21.120601.140946

4. Tonks, N. K., Diltz, C. D., & Fischer, E. H. (1990). CD45, an integral membrane protein tyrosine phosphatase. Characterization of enzyme activity. The Journal of biological chemistry.

5. Nam, H. J., Poy, F., Saito, H., & Frederick, C. A. (2005). Structural basis for the function and regulation of the receptor protein tyrosine phosphatase CD45. The Journal of experimental medicine. https://doi.org/10.1084/jem.20041890

6. Rheinlander, A., Schraven, B., & Bommhardt, U. (2018). CD45 in human physiology and clinical medicine. Immunology letters. https://doi.org/10.1016/j.imlet.2018.01.009

Long Name

Cluster of Differentiation 45

Alternate Names

CD45, LCA, PTPRC, T200 Glycoprotein

Gene Symbol

PTPRC

Additional CD45 Products

Product Documents for CD45 Antibody (BL-178-12C7)

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for CD45 Antibody (BL-178-12C7)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.